Physician profile
Andrew Townsend
NPI 1740207760
$432.87
in general payments reported to CMS, 2019-2025
16 companies · $239 in 2025
The $239 reported for 2025 was more than what 79% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $17.77 · 2023: $17.70 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $257.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $84.24 | 2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $64.58 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $36.84 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $31.03 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $28.72 | 2019 | |
| Pfizer INC. | $23.86 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.48 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $20.02 | 2019 | |
| Allergan, INC. | $17.77 | 2020 | |
| Genentech USA, INC. | $17.46 | 2019 | |
| Grifols USA, LLC | $17.20 | 2019 | |
| Merck Sharp & Dohme LLC | $16.55 | 2025 | Enflonsia |
| Amgen INC. | $14.94 | 2019 | |
| Glaxosmithkline, LLC. | $13.34 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.07 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Townsend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.